

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

- 1-4. (Canceled)
5. (Withdrawn) An agent which inhibits, facilitates, or modulates the helicase, ATPase activity of MTT1.
6. (Withdrawn) The agent of claim 5, wherein the agent is a ribozyme, antisense molecule, or ligand which acts as an antagonist of agonist of translation termination.
7. (Canceled)
8. (Canceled)
9. (Withdrawn) An antibody which binds to the complex of claim 7.
10. (Withdrawn) The antibody of claim 9, wherein the antibody is a monoclonal or polyclonal.
11. (Withdrawn) The antibody of claim 9, wherein the antibody has a label.
12. (Withdrawn) An agent which binds to the complex of claims 7 or 8.
13. (Withdrawn) An agent which inhibits or modulates the binding of human MTT1 to eRF3; or MTT1 or a polysome.

14. (Withdrawn) An agent which facilitates the binding of human MTT1 to eRF3; or MTT1 or a polysome.
15. (Withdrawn) The agent of claim 12, wherein the agent has a label or marker.
16. (Withdrawn) The agent of claim 14, wherein the agent is an antisense molecule or a ribozyme.
17. (Withdrawn) A method of modulating peptidyl transferase activity during translation, comprising contacting a cell with the complex of claim 7 in an amount effective to facilitate translation termination, thereby modulating the peptidyl transferase activity.
18. (Withdrawn) A method of modulating peptidyl transferase activity during translation, comprising contacting a cell with the agent of claim 12, in an amount effective to suppress nonsense translation termination, thereby modulating the peptidyl transferase activity.
19. (Withdrawn) The method of claim 18, wherein the peptidyl transferase activity during translation comprises initiation, elongation, termination and degradation of mRNA.
20. (Withdrawn) A method of modulating the efficiency of translation termination of mRNA at a nonsense codon and/or promoting degradation of aberrant transcripts, comprising contacting a cell with the agent of claim 12, in an amount effective to modulate the efficiency of translation termination of mRNA at a nonsense codon and/or promoting degradation of aberrant transcripts.
21. (Withdrawn) A method of screening for drug involved in peptidyl transferase activity during translation comprising: a) contacting cells with a candidate drug; and b) assaying for modulation of the complex of claims 7, wherein a drug that modulates complex is involved in peptidyl transferase activity.

22. (Withdrawn) A method of screening for a drug active involved in enhancing translation termination comprising: a) contacting cells with a candidate drug; and b) assaying for modulating of the protein complex of claims 7; wherein a drug that modulates protein complex is involved in enhancing translation termination.
23. (Withdrawn) A method of screening for a drug involved in enhancing translation termination comprising: a) incubating the drug and the complex; and b) measuring the effect on nonsense suppression, thereby screening for a drug involved in enhancing translation termination.
24. (Withdrawn) The method of claim 23, wherein the assay is a RNA assay or a ATPase assay.
25. (Withdrawn) A method of screening for a drug which inhibits the interaction between MTT1 and eRF3, comprising: a) contacting cells with a candidate drug; and b) assaying for modulation of the complex of claim 7, wherein a drug that modulates the binding of MTT1 to eRF3 is involved in enhancing translation termination.
26. (Withdrawn) A method of modulating the efficiency of translation termination of mRNA and/or degradation of aberrant transcripts in a cell, said method comprising: a) providing a cell containing a vector comprising the nucleic acid encoding the complex of claim 7; or an antisense thereof; b) overexpressing said vector in said cell to produce an overexpressed complex so as to interfere with the function of the complex.
27. (Withdrawn) A method for identifying a disease state involving a defect in the complex of claim 7 comprising: (a) transfecting a cell with a nucleic acid which encodes the complex; (b) determining the proportion of the defective complex of the cell after transfection; (c) comparing the proportion of the defective complex of the cell after transfection with the proportion of defective complex of the cell before transfection.

28. (Withdrawn) A method for treating a disease associated with peptidyl transferase activity, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising the complex of claim 7 or the agent of claim 12, and a pharmaceutical carrier or diluent, thereby treating the subject.

29. (Withdrawn) The method of claim 28, wherein the disease results from a nonsense or frameshift mutation.

30. (Withdrawn) The method of claim 29, wherein the disease is  $\beta$ -thalassemia,  $\beta$ -globin, Duchenne/Becker Muscular Dystrophy, Hemophilia A, Hemophilia B, Von Willebrand Disease, Osteogenesis Imperfecta (OI), Breast cancer, Ovarian Cancer, Wilms Tumor, Hirschsprung disease, Cystic fibrosis, Kidney Stones, Familial hypercholesterolemia (FH), Retinitis Pigmentosa, or Neurofibromatosis, Retinoblastoma, ATM, Costmann disease.

31. (Withdrawn) A method for identifying a disease state involving defective multimeric proteins comprising:

- (a) transfecting a cell with the vector of claim;
- (b) determining the proportion of defective multimeric proteins of the cell after transfection;
- (c) comparing the proportion of defective multimeric proteins of the cell after transfection with the proportion of defective multimeric proteins of the cell before transfection.

32. (Withdrawn) A method of identifying genes which are involved in modulation of translation termination, which comprises: a) isolated a gene of interest; and b) determining whether the gene of interest comprises motifs I-IX, wherein if the gene comprises any one of the nine motifs the gene modulates translation fidelity including initiation, elongation, termination, termination, decay.

33. (Withdrawn) The method of claim 32, wherein the motif I comprises the sequence:  
GppGTKTxT-X(n).

34. (Withdrawn) The method of claim 32, wherein the motif II comprises the sequence  
riLxcaSNxAxDxl-X(n).

35. (Withdrawn) The method of claim 32, wherein the motif III comprises the sequence  
vviDExxQaxxxxxiPi-X(n).

36. (Withdrawn) The method of claim 32, wherein the motif IV comprises the sequence  
xxilaGDxxQLp-X(n).

37. (Withdrawn) The method of claim 32, wherein the motif V comprises the sequence  
lxxSLFerv-X(n).

38. (Withdrawn) The method of claim 32, wherein the motif VI comprises the sequence  
LxxQYRMhpxisefpxYxgxL-X(n).

39. (Withdrawn) The method of claim 32, wherein the motif VII comprises the sequence  
IgvitPYxxQvxxl-X(n).

40. (Withdrawn) The method of claim 32, wherein the motif VIII comprises the sequence  
vevxtVDxFQGreKdxliSc VR-X(n).

41. (Withdrawn) The method of claim 32, wherein the motif IX comprises the sequence  
iGFLxdxRRINValTRak.

42. (New) An isolated multiprotein complex comprising a eukaryotic Modulator of Translation Termination protein (Mtt1p, also referred to as helicase B), a eukaryotic Upf1 protein, a peptidyl

eukaryotic release factor 1 (eRF1) and a peptidyl eukaryotic release factor 3 (eRF3), wherein the components of the complex are from the same eukaryotic source and wherein the complex is effective to modulate peptidyl transferase activity during translation.

43. (New) The complex of claim 42, further comprising a eukaryotic Upf2 protein.

44. (New) The complex of claim 42, further comprising a eukaryotic Upf3 protein.

45. (New) The complex of claim 42, wherein to be effective in modulating the fidelity of translation termination, a eukaryotic Mtt1p should comprise at least one of the motifs selected from the group consisting of GppGTKTxT-X(n), riLxcaSNxAxDxl-X(n), vviDExxQaxxxxxiPi-X(n), xxilaGDxxQLp-X(n), lxxSLFerv-X(n), LxxQYRMhpxisefpxYxgxL-X(n), IgvitPYxxQvxxl-X(n), vevxtVDxFQGreKdxlilScVR-X(n) and iGFLxdxRRINValTRak.

46. (New) The complex of claim 42, wherein the complex modulates the efficiency of translation termination.

47. (New) The complex of claim 42, wherein the complex modulates the degradation of aberrant mRNA.

48. (New) The complex of claim 42, wherein the eukaryotic source is a yeast.

49. (New) The complex of claim 48, wherein the yeast is *Saccharomyces cerevisiae*.